AR082201A1 - Bencenosulfonamidas utiles como inhibidores del canal de sodio - Google Patents
Bencenosulfonamidas utiles como inhibidores del canal de sodioInfo
- Publication number
- AR082201A1 AR082201A1 ARP110102479A ARP110102479A AR082201A1 AR 082201 A1 AR082201 A1 AR 082201A1 AR P110102479 A ARP110102479 A AR P110102479A AR P110102479 A ARP110102479 A AR P110102479A AR 082201 A1 AR082201 A1 AR 082201A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- cycloalkyl
- alkyl
- ring
- heteroaryl
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229940124777 Nav1.7 inhibitor Drugs 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36292710P | 2010-07-09 | 2010-07-09 | |
| US201161492525P | 2011-06-02 | 2011-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082201A1 true AR082201A1 (es) | 2012-11-21 |
Family
ID=45439019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102479A AR082201A1 (es) | 2010-07-09 | 2011-07-08 | Bencenosulfonamidas utiles como inhibidores del canal de sodio |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8772293B2 (OSRAM) |
| EP (1) | EP2590951B1 (OSRAM) |
| JP (1) | JP5830534B2 (OSRAM) |
| AR (1) | AR082201A1 (OSRAM) |
| CA (1) | CA2804593C (OSRAM) |
| ES (1) | ES2533065T3 (OSRAM) |
| UY (1) | UY33491A (OSRAM) |
| WO (1) | WO2012004743A1 (OSRAM) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5860045B2 (ja) | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| ES2525581T3 (es) | 2010-07-12 | 2014-12-26 | Pfizer Limited | Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| WO2012007868A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| EP2593427B1 (en) | 2010-07-12 | 2014-12-24 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| RU2014121983A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств |
| US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| WO2013137371A1 (ja) * | 2012-03-15 | 2013-09-19 | 興和株式会社 | 新規ピリミジン化合物及びそれらを含有する医薬 |
| WO2013161928A1 (ja) * | 2012-04-26 | 2013-10-31 | 塩野義製薬株式会社 | オキサゾロトリアゾール誘導体およびそれらを含有する医薬組成物 |
| US8952169B2 (en) | 2012-05-22 | 2015-02-10 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
| CN104797555B (zh) | 2012-07-06 | 2017-12-22 | 基因泰克公司 | N‑取代的苯甲酰胺及其使用方法 |
| CA2887845C (en) * | 2012-10-15 | 2020-12-15 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| US9388179B2 (en) | 2012-10-26 | 2016-07-12 | Merck Sharp & Dohme Corp. | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
| HK1213476A1 (zh) | 2013-03-14 | 2016-07-08 | 基因泰克公司 | 取代的三唑並吡啶及其使用方法 |
| CA2900604A1 (en) * | 2013-03-15 | 2014-09-25 | Chromocell Corporation | Sodium channel modulators for the treatment of pain |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| CN105611923B (zh) * | 2013-09-10 | 2019-08-23 | 卓莫赛尔公司 | 用于治疗疼痛和糖尿病的钠通道调节剂 |
| CA2931732A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| US10468036B2 (en) * | 2014-04-30 | 2019-11-05 | Accusonus, Inc. | Methods and systems for processing and mixing signals using signal decomposition |
| CA2950393A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Benzenesulfonamides useful as sodium channel inhibitors |
| WO2016007534A1 (en) | 2014-07-07 | 2016-01-14 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| WO2016034971A1 (en) | 2014-09-04 | 2016-03-10 | Pfizer Limited | Sulfonamides derivatives as urat1 inhibitors |
| PE20180575A1 (es) | 2015-05-22 | 2018-04-04 | Genentech Inc | Benzamidas sustituidas y metodos para utilizarlas |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| BR112018006189A2 (pt) | 2015-09-28 | 2018-10-09 | Genentech Inc | compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto |
| US10316026B2 (en) | 2015-11-06 | 2019-06-11 | Daiichi Sankyo Company, Limited | Method for removing dimethoxybenzyl group |
| JP2018535234A (ja) | 2015-11-25 | 2018-11-29 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル遮断薬として有用な置換ベンズアミド |
| EP3390374B1 (en) | 2015-12-18 | 2020-08-26 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN109071426A (zh) | 2016-03-30 | 2018-12-21 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| CA3023465C (en) | 2016-05-20 | 2024-09-24 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| WO2018072602A1 (en) | 2016-10-17 | 2018-04-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| AU2017371674B2 (en) | 2016-12-09 | 2021-07-22 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| CN112262142B (zh) | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
| MA53489A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques |
| US10752623B2 (en) | 2018-08-31 | 2020-08-25 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| EP3891157A4 (en) | 2018-12-05 | 2022-08-31 | Merck Sharp & Dohme Corp. | 4-AMINO- OR 4-ALKOXY-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATE SODIUM CHANNELS |
| TW202216671A (zh) * | 2020-06-25 | 2022-05-01 | 瑞士商諾華公司 | １，４—二取代的嗒𠯤化合物之製造方法 |
| CN119013013A (zh) * | 2021-12-23 | 2024-11-22 | 维拉洛斯治疗公司 | 用于治疗12-脂加氧酶(12-lox)介导的疾病的组合物和使用方法 |
| WO2025160284A1 (en) * | 2024-01-23 | 2025-07-31 | The Board Of Trustees Of The University Of Illinois | Algorithm for computer-assisted molecular modularization |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR71915B (OSRAM) | 1979-11-27 | 1983-08-16 | Pfizer | |
| EP0194599A3 (en) | 1985-03-14 | 1988-01-20 | Nissan Chemical Industries Ltd. | Benzamide derivatives, process for producing the same, and soil fungicides containing the same |
| US5084085A (en) | 1986-08-20 | 1992-01-28 | Fmc Corporation | Herbicidal aryloxyphenyltriazolinones and related compounds |
| WO1988001133A1 (en) | 1986-08-20 | 1988-02-25 | Fmc Corporation | Herbicides |
| US4845264A (en) | 1987-03-05 | 1989-07-04 | Teijin Limited | Phenoxycarboxylic acid and herbicide comprising it as active ingredient |
| US4920133A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920130A (en) | 1987-11-02 | 1990-04-24 | Rorer Pharamceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920132A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920131A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| EP0325245B1 (en) | 1988-01-19 | 1993-10-20 | Tanabe Seiyaku Co., Ltd. | Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use |
| GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
| PT94960A (pt) | 1989-08-11 | 1991-04-18 | Ici Plc | Processo para a preparacao de derivados de quinolina e de composicoes farmaceuticas que as contem |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0453210A3 (en) | 1990-04-19 | 1993-01-13 | Imperial Chemical Industries Plc | Pyridine derivatives |
| WO1993000332A1 (en) | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| GB2266527A (en) | 1992-03-17 | 1993-11-03 | Merck & Co Inc | Substituted azetidinones useful in the treatment of leukemia |
| JPH05289262A (ja) | 1992-04-10 | 1993-11-05 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| JPH05307242A (ja) | 1992-04-28 | 1993-11-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| JP3101848B2 (ja) | 1992-05-15 | 2000-10-23 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料 |
| FR2694295B1 (fr) | 1992-07-28 | 1994-09-02 | Adir | Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent. |
| AU5802894A (en) | 1992-12-17 | 1994-07-04 | Merck & Co., Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
| EP0617001B1 (en) | 1993-03-19 | 2000-01-26 | Merck & Co. Inc. | Phenoxyphenylacetic acid derivatives |
| JPH06347968A (ja) | 1993-04-14 | 1994-12-22 | Fuji Photo Film Co Ltd | ハロゲン化銀感光材料 |
| DK77393D0 (da) | 1993-06-29 | 1993-06-29 | Novo Nordisk As | Aktivering af enzymer |
| JP3503839B2 (ja) | 1994-05-25 | 2004-03-08 | 富士写真フイルム株式会社 | ポジ型感光性組成物 |
| JPH10503779A (ja) | 1994-08-08 | 1998-04-07 | メルク エンド カンパニー インコーポレーテッド | フェノキシフェニル酢酸誘導体 |
| AU3642795A (en) | 1994-09-27 | 1996-04-19 | Merck & Co., Inc. | Endothelin receptor antagonists for the treatment of emesis |
| US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
| GB9514031D0 (en) | 1995-07-10 | 1995-09-06 | Zeneca Ltd | Chemical process |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| JP3519218B2 (ja) | 1996-08-14 | 2004-04-12 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料および画像形成方法 |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP0995742A4 (en) | 1997-06-27 | 2004-08-25 | Fujisawa Pharmaceutical Co | SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE |
| US6555584B1 (en) | 2000-06-29 | 2003-04-29 | Ajinomoto Co., Inc. | Acylsulfonamide derivative |
| DE19742951A1 (de) | 1997-09-29 | 1999-04-15 | Hoechst Schering Agrevo Gmbh | Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung |
| EA200000427A1 (ru) | 1997-10-17 | 2001-02-26 | Авентис Фармасьютикалз Продактс Инк. | Терапевтические применения хинолиновых производных |
| AU1529799A (en) | 1997-12-23 | 1999-07-12 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
| GB9805520D0 (en) | 1998-03-17 | 1998-05-13 | Zeneca Ltd | Chemical compounds |
| GT199900044A (es) | 1998-04-10 | 2000-09-14 | Procedimientos para preparar haluros de fenoxifenilsulfonilo. | |
| DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
| GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| CA2371308A1 (en) | 1999-04-28 | 2000-11-02 | Aventis Pharma Deutschland Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| AU776773B2 (en) | 1999-05-05 | 2004-09-23 | Cubist Pharmaceuticals, Inc. | Novel catechols as antimicrobial agents |
| JP2003500387A (ja) | 1999-05-24 | 2003-01-07 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子の阻害剤 |
| EP1183235A2 (en) | 1999-05-24 | 2002-03-06 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| AU5155500A (en) | 1999-05-24 | 2000-12-12 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| JP2001075213A (ja) | 1999-09-07 | 2001-03-23 | Fuji Photo Film Co Ltd | ハロゲン化銀写真乳剤、その製造方法及びこれを用いたハロゲン化銀写真感光材料 |
| WO2001023347A1 (en) | 1999-09-29 | 2001-04-05 | Novo Nordisk A/S | Novel aromatic compounds |
| SK4732002A3 (en) | 1999-10-13 | 2002-12-03 | Pfizer Prod Inc | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| JP2004500389A (ja) | 2000-03-09 | 2004-01-08 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｐｐａｒメディエーターの治療での使用 |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| EP1260221A3 (en) | 2001-05-23 | 2002-12-18 | Pfizer Products Inc. | Combination treatment for depression and anxiety |
| SE0101978D0 (sv) | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | New compounds |
| JP4554926B2 (ja) | 2001-11-16 | 2010-09-29 | 富山化学工業株式会社 | 新規なベンゾフェノン誘導体またはその塩 |
| EP1556038A2 (en) | 2002-08-26 | 2005-07-27 | Merck & Co., Inc. | Acetophenone potentiators of metabotropic glutamate receptors |
| AU2003273762A1 (en) | 2002-10-28 | 2004-05-13 | Novo Nordisk A/S | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| WO2004078126A2 (en) | 2003-02-28 | 2004-09-16 | Oxigene, Inc. | Compositions and methods with enhanced therapeutic activity |
| KR20060073930A (ko) | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| CN1922151A (zh) | 2004-02-12 | 2007-02-28 | 特兰斯泰克制药公司 | 取代的吡咯衍生物、组合物和使用方法 |
| GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
| US7880000B2 (en) | 2004-05-07 | 2011-02-01 | Amgen Inc. | Protein kinase modulators and method of use |
| EP1773792A1 (en) | 2004-07-30 | 2007-04-18 | Merck & Co., Inc. | Indanone potentiators of metabotropic glutamate receptors |
| MX2007004781A (es) | 2004-10-20 | 2007-05-11 | Applied Research Systems | Derivados de 3-arilamino piridina. |
| JP2008189549A (ja) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| US20080293775A1 (en) | 2005-12-15 | 2008-11-27 | Astrazeneca Ab | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease |
| JP2009057282A (ja) | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
| WO2007115408A1 (en) | 2006-04-10 | 2007-10-18 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| GEP20125425B (en) | 2006-10-18 | 2012-03-26 | Pfizer Prod Inc | Biaryl ether urea compounds |
| SI2118074T1 (sl) | 2007-02-01 | 2014-05-30 | Resverlogix Corp. | Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni |
| ES2340640T3 (es) | 2007-03-23 | 2010-06-07 | Icagen, Inc. | Inhibidores de canales de iones. |
| BRPI0810202A2 (pt) | 2007-05-03 | 2014-10-21 | Pfizer Ltd | Derivados de piridina |
| TW200911245A (en) | 2007-06-07 | 2009-03-16 | Astellas Pharma Inc | Pyridone derivatives |
| EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
| NZ584474A (en) | 2007-10-11 | 2012-06-29 | Vertex Pharma | Amides useful as inhibitors of voltage-gated sodium channels |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| TW200930368A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| WO2009067541A2 (en) | 2007-11-20 | 2009-05-28 | Gilead Sciences, Inc. | Integrase inhibitors |
| EP2222639A1 (en) | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| GB0725214D0 (en) | 2007-12-24 | 2008-02-06 | Karobio Ab | Pharmaceutical compounds |
| JP2011514326A (ja) | 2008-02-15 | 2011-05-06 | ビーエーエスエフ ソシエタス・ヨーロピア | 置換スルホン酸アミド化合物 |
| EP2119690A1 (en) | 2008-05-14 | 2009-11-18 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Radiolabelled MMP selective compounds |
| US20110077154A1 (en) | 2008-05-28 | 2011-03-31 | Basf Se | Substituted pyridin-4-yl-methyl sulfonamides as fungicides |
| RU2481329C2 (ru) | 2008-06-23 | 2013-05-10 | Астеллас Фарма Инк. | Сульфонамидные соединения или их соли |
| US8107894B2 (en) | 2008-08-12 | 2012-01-31 | Raytheon Company | Modular solid-state millimeter wave (MMW) RF power source |
| GEP20135992B (en) * | 2009-01-12 | 2013-12-25 | Icagen Inc | Sulfonamide derivatives |
| JP5289262B2 (ja) | 2009-09-30 | 2013-09-11 | 京セラドキュメントソリューションズ株式会社 | シート搬送装置とこれを備えた画像読取装置及び画像形成装置 |
| ES2532356T3 (es) * | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| JP5860045B2 (ja) * | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| WO2012007868A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| EP2593427B1 (en) | 2010-07-12 | 2014-12-24 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| ES2525581T3 (es) | 2010-07-12 | 2014-12-26 | Pfizer Limited | Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje |
-
2011
- 2011-07-05 EP EP11746620.1A patent/EP2590951B1/en not_active Not-in-force
- 2011-07-05 WO PCT/IB2011/052974 patent/WO2012004743A1/en not_active Ceased
- 2011-07-05 CA CA2804593A patent/CA2804593C/en not_active Expired - Fee Related
- 2011-07-05 ES ES11746620.1T patent/ES2533065T3/es active Active
- 2011-07-05 JP JP2013519189A patent/JP5830534B2/ja not_active Expired - Fee Related
- 2011-07-07 UY UY0001033491A patent/UY33491A/es not_active Application Discontinuation
- 2011-07-08 AR ARP110102479A patent/AR082201A1/es not_active Application Discontinuation
- 2011-07-08 US US13/178,534 patent/US8772293B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8772293B2 (en) | 2014-07-08 |
| ES2533065T3 (es) | 2015-04-07 |
| UY33491A (es) | 2012-02-29 |
| WO2012004743A1 (en) | 2012-01-12 |
| CA2804593A1 (en) | 2012-01-12 |
| CA2804593C (en) | 2015-11-24 |
| US20120010182A1 (en) | 2012-01-12 |
| JP5830534B2 (ja) | 2015-12-09 |
| EP2590951A1 (en) | 2013-05-15 |
| JP2013531031A (ja) | 2013-08-01 |
| EP2590951B1 (en) | 2015-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082201A1 (es) | Bencenosulfonamidas utiles como inhibidores del canal de sodio | |
| AR082153A1 (es) | N-sulfonilbenzamidas utiles como inhibidor del canal de sodio | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| PH12021550167A1 (en) | Heterobicyclic compounds for inhibiting the activity of shp2 | |
| AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
| CO5590957A2 (es) | Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas | |
| ES2620379T3 (es) | Quinolina y quinoxalina amidas como moduladores de canales de sodio | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR071617A1 (es) | Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. | |
| ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| PE20150400A1 (es) | Benzamidas n-sustituidas y su uso en el tratamiento del dolor | |
| PH12016501007A1 (en) | Substituted benzamides and methods of use thereof | |
| PE20151794A1 (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| RU2014140735A (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR077440A1 (es) | Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| PE20141041A1 (es) | Compuestos, metodos y formulaciones parasiticidas | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |